查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2068685

2034年醫藥中間體市場預測－按產品類型、合成類型、治療領域、應用、最終用戶和地區分類的全球分析

Pharmaceutical Intermediates Market Forecasts to 2034 - Global Analysis By Product Type, Synthesis Type, Therapeutic Area, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球醫藥中間體市場規模將達到 2,345 億美元，並在預測期內以 6.8% 的複合年成長率成長，到 2034 年將達到 3,969 億美元。

醫藥中間體是合成活性藥物成分（API）和成品藥的關鍵化合物。這些中間體在轉化為治療藥物之前，需要經歷各種化學反應和純化過程。該市場涵蓋範圍廣泛，包括整體藥物研發和生產的各個環節的有機和無機化學品，例如高級中間體、基礎中間體和精細化學品。全球醫療保健支出不斷成長、慢性病盛行率上升以及學名藥生產的擴張，正推動全球對高品質醫藥中間體的持續需求。

對學名藥的需求增加以及成本效益高的生產方式

全球醫療保健產業正致力於在保證品質標準的同時降低藥品成本，這推動了醫藥中間體市場的發展。大規模生產學名藥需要大量的中間體，而且隨著重磅藥物專利到期和學名藥進入市場，這種需求還在不斷成長。製藥公司和契約製造組織（CMO）正在擴大其間體採購能力，尤其是在生產成本較低的新興市場，以滿足這一需求。醫療服務提供者在控制成本的同時擴大基本藥物的可及性，這進一步加劇了對可靠且經濟高效的中間體供應鏈的需求，該供應鏈能夠實現學名藥的大規模生產。

嚴格的監管和品質合規要求

這一因素正顯著阻礙市場成長，因為醫藥中間體面臨包括FDA、EMA和其他監管機構在內的衛生部門日益嚴格的審查。中間體必須符合嚴格的純度、穩定性和安全性標準，這需要對品管系統、文件記錄和生產流程驗證進行大量投資。即使是微小的偏差也可能導致生產延誤、批次不合格或供應鏈中斷。中小製造商，尤其是在發展中地區的製造商，難以持續遵守不斷變化的藥品生產品質管理規範（GMP）指南。這種監管負擔增加了營運成本，阻礙了新供應商進入市場，限制了市場擴張，並導致擁有完善品管系統的現有公司將生產集中化。

合約研發生產機構（CDMO）的擴張

隨著製藥公司擴大將中間體和原料藥(API) 的生產外包給專業合作夥伴，這一趨勢為醫藥中間體供應商帶來了巨大的商機。合約研發生產機構 (CDMO) 透過提供複雜化學合成的專業知識、放大生產能力和法規遵從方面的專業知識，使製藥公司能夠專注於研發和商業化。小分子藥物研發管線的擴展，尤其是在腫瘤和罕見疾病領域，正在推動對新型中間體客製合成的需求。隨著 CDMO 拓展其全球企業發展，尤其是在亞太地區，對標準和客製化中間體的新需求正在湧現，這為能夠滿足嚴格的品質和交付要求的供應商創造了成長機會。

供應鏈中斷與原物料價格波動

地緣政治緊張局勢、貿易限制和自然災害擾亂了關鍵原料的流通，對醫藥中間體市場構成重大威脅。許多關鍵起始原料和試劑集中產於特定地區，因此極易受到出口限制和生產中斷的影響。新冠感染疾病暴露了醫藥原料對特定國家的過度依賴，導致監管機構的審查，並凸顯了這些依賴的脆弱性。石油衍生原料和特種化學品的價格波動會影響中間體的生產成本，擠壓與製藥企業簽訂固定價格合約的供應商的利潤空間，如果供應鏈中斷，還可能導致基本藥物短缺。

新型冠狀病毒（COVID-19）的影響：

新冠疫情為醫藥中間體市場帶來了挑戰和機遇，從根本上重塑了供應鏈策略。早期封鎖措施擾亂了生產和物流，導致多個治療領域的藥物生產出現中間體短缺和延誤。然而，抗病毒藥物、疫苗和輔助療法的迫切需求激增，加速了對某些中間體的需求，尤其是用於瑞德西韋和地塞米松等治療藥物的中間體。各國政府和製藥公司認知到中間體生產自給自足的戰略重要性，推動了生產多元化和區域性生產激勵措施。這種對供應穩定性的高度重視持續影響籌資策略，使擁有地域分散的生產能力和完善的業務永續營運計劃的供應商更受青睞。

在預測期內，API細分市場預計將佔據最大的市場佔有率。

在預測期內，原料藥（API）領域預計將佔據最大的市場佔有率。這是因為活性藥物成分（API）是最終的化學產品，需要大量的中間體。任何API的合成都涉及多個中間體步驟，從基礎組分到高級中間體，最終才能得到活性化合物。受疾病盛行率上升和人口老化的影響，品牌藥和學名藥對API的全球需求不斷成長，這直接導致中間體消耗量增加。此外，專科藥和生物製藥領域對複雜API的需求趨勢也需要合成客製化的中間體，從而支撐了長期需求。大型製藥公司和合約研發生產機構（CDMO）正在投入大量採購預算用於API生產所需的中間體，這鞏固了該領域的領先地位。

在預測期內，合約開發和生產組織 (CDMO) 領域預計將呈現最高的複合年成長率。

在預測期內，隨著製藥公司擴大將中間體和原料藥的生產外包給專業合作夥伴，合約研發生產機構（CDMO）領域預計將呈現最高的成長率。 CDMO提供從製程開發到商業化生產的一體化服務，使藥物研發公司能夠降低資本支出並縮短產品上市時間。隨著包括抗體藥物複合體（ADC）和標靶治療的小分子候選藥物變得越來越複雜，CDMO在先進化學合成和純化技術方面的專業知識需求日益成長。此外，亞太和東歐的CDMO憑藉其成本優勢以及不斷提升的品質和合規性，正贏得西方製藥公司的外包合約。這種外包趨勢正在透過與CDMO的合作，持續推動對中間體生產服務的需求。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於大型製藥企業的強大實力、完善的醫療保健基礎設施以及對藥物研發的大量投資。作為全球最大的藥品市場，美國對創新藥和學名藥的生產都需要大量的中間體。該地區嚴格的監管標準也促使企業使用來自可靠供應商的高品質中間體。此外，為減少對海外供應鏈的依賴，製藥生產回流的趨勢正在加速發展，這進一步支撐了北美對中間體的需求。這些因素共同作用，預計將使該地區在整個預測期內保持其市場主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於中國、印度和東南亞國家製藥業的快速擴張。低廉的生產成本、豐富的原料供應以及政府促進國內製藥生產的舉措，使該地區成為中間體製造地的理想地點。歐洲和美洲市場擴大將中間體和原料藥（API）的生產外包給亞太地區的合約研發生產機構（CDMO），進一步加速了該地區的市場成長。此外，該地區醫療保健支出不斷成長、慢性病負擔日益加重以及學名藥消費量不斷增加，也創造了持續的本地需求。隨著製藥基礎設施的不斷發展，亞太地區正成為醫藥中間體市場成長最快的地區。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球醫藥中間體市場：依產品類型分類

  • 基礎中級
  • 中高級
  • API 中級
  • 掌性中間體
  • 特殊中間體

第6章 全球醫藥中間體市場：依合成類型分類

  • 合成
  • 生物基
  • 發酵衍生的

第7章 全球醫藥中間體市場：依治療領域分類

  • 腫瘤學
  • 心血管系統
  • 神經病學
  • 抗感染藥物
  • 糖尿病
  • 其他治療領域

第8章 全球醫藥中間體市場：依應用領域分類

  • API
  • 學名藥
  • 品牌藥品
  • 特種藥品

第9章 全球醫藥中間體市場：依最終用戶分類

  • 製藥公司
  • 契約製造組織
  • 合約研發生產組織（CDMO）
  • 研究機構

第10章 全球醫藥中間體市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • BASF SE
  • Lonza Group AG
  • Evonik Industries AG
  • Cambrex Corporation
  • Dishman Carbogen Amcis Limited
  • Aarti Industries Limited
  • Jubilant Pharmova Limited
  • Albemarle Corporation
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • Pfizer CentreOne
  • Boehringer Ingelheim International GmbH
  • CordenPharma International
  • Patheon NV
  • Hovione Holding Ltd.
  • WuXi AppTec Co. Ltd.
  • Recipharm AB
  • Siegfried Holding AG
  • Laurus Labs Limited
  • Dr. Reddy's Laboratories Limited
Product Code: SMRC37147

According to Stratistics MRC, the Global Pharmaceutical Intermediates Market is accounted for $234.5 billion in 2026 and is expected to reach $396.9 billion by 2034 growing at a CAGR of 6.8% during the forecast period. Pharmaceutical intermediates are chemical compounds that serve as crucial building blocks in the synthesis of active pharmaceutical ingredients (APIs) and finished drug products. These intermediates undergo various chemical reactions and purification steps before being transformed into therapeutically effective medications. The market encompasses a wide range of organic and inorganic chemicals, including advanced intermediates, basic intermediates, and fine chemicals used across drug development and manufacturing. Rising global healthcare expenditure, increasing prevalence of chronic diseases, and expanding generic drug production are driving consistent demand for high-quality pharmaceutical intermediates worldwide.

Market Dynamics:

Driver:

Increasing demand for generic drugs and cost-effective manufacturing

This factor is significantly driving the pharmaceutical intermediates market as healthcare systems worldwide seek to reduce medication costs while maintaining quality standards. Generic drugs require substantial volumes of intermediates for large-scale production, particularly as blockbuster drugs lose patent protection and generic alternatives enter the market. Pharmaceutical companies and contract manufacturing organizations are expanding their intermediate sourcing capabilities to meet this demand, especially in emerging economies where manufacturing costs are lower. The pressure on healthcare providers to contain expenses while expanding access to essential medicines further accelerates the need for reliable, cost-effective intermediate supply chains that enable affordable generic drug production at scale.

Restraint:

Stringent regulatory and quality compliance requirements

This factor significantly restrains market growth as pharmaceutical intermediates face increasingly rigorous oversight from health authorities including the FDA, EMA, and other regulatory bodies. Intermediates must meet strict purity, stability, and safety standards, requiring substantial investment in quality control systems, documentation, and manufacturing process validation. Any deviation can lead to production delays, batch rejections, or supply chain disruptions. Smaller manufacturers, particularly in developing regions, struggle to maintain compliance with evolving Good Manufacturing Practice guidelines. This regulatory burden increases operational costs and creates barriers to entry for new suppliers, limiting market expansion and consolidating production among established players with robust quality management systems.

Opportunity:

Expansion of contract development and manufacturing organizations

This factor presents substantial opportunities for pharmaceutical intermediates providers as pharmaceutical companies increasingly outsource intermediate and API production to specialized partners. Contract Development and Manufacturing Organizations (CDMOs) offer expertise in complex chemical synthesis, scale-up capabilities, and regulatory compliance, enabling drug sponsors to focus on research and commercialization. The growing pipeline of small molecule drugs, particularly in oncology and rare diseases, requires custom synthesis of novel intermediates. As CDMOs expand their global footprint, particularly in Asia-Pacific regions, they create new demand for both standard and custom intermediates, offering growth opportunities for suppliers capable of meeting stringent quality and delivery requirements.

Threat:

Supply chain disruptions and raw material price volatility

This factor poses a significant threat to the pharmaceutical intermediates market as geopolitical tensions, trade restrictions, and natural disasters disrupt the flow of essential raw materials. Many key starting materials and reagents are sourced from concentrated geographic regions, creating vulnerability to export controls or production shutdowns. The COVID-19 pandemic exposed critical dependencies on specific countries for pharmaceutical inputs, prompting regulatory scrutiny but also highlighting fragility. Fluctuating prices of petroleum-based feedstocks and specialty chemicals impact intermediate manufacturing costs, squeezing profit margins for suppliers operating under fixed-price contracts with drug manufacturers, and potentially leading to shortages of essential medications if supply chains are compromised.

Covid-19 Impact:

The COVID-19 pandemic created both challenges and opportunities for the pharmaceutical intermediates market, fundamentally reshaping supply chain strategies. Initial lockdowns disrupted manufacturing and logistics, causing intermediate shortages and delaying drug production across multiple therapeutic categories. However, the urgent need for antiviral medications, vaccines, and supportive therapies accelerated demand for certain intermediates, particularly those used in treatments like remdesivir and dexamethasone. Governments and pharmaceutical companies recognized the strategic importance of intermediate manufacturing self-sufficiency, leading to diversification initiatives and regional production incentives. This heightened awareness of supply security continues to influence procurement strategies, favoring suppliers with geographically distributed manufacturing capabilities and robust business continuity plans.

The APIs segment is expected to be the largest during the forecast period

The APIs segment is expected to account for the largest market share during the forecast period, as active pharmaceutical ingredients represent the final chemical output requiring substantial quantities of pharmaceutical intermediates. Every API synthesis involves multiple intermediate steps, from basic building blocks to advanced intermediates, before reaching the final active compound. The growing global demand for both branded and generic APIs, driven by rising disease prevalence and aging populations, directly translates to increased intermediate consumption. Furthermore, the trend toward complex APIs for specialty medications and biologics requires custom intermediate synthesis, sustaining long-term demand. Major pharmaceutical companies and CDMOs allocate significant procurement budgets to intermediate sourcing for API production, cementing this segment's dominance.

The Contract Development and Manufacturing Organizations segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Contract Development and Manufacturing Organizations segment is predicted to witness the highest growth rate, as pharmaceutical companies increasingly outsource intermediate and API production to specialized partners. CDMOs offer integrated services from process development through commercial manufacturing, enabling drug sponsors to reduce capital expenditure and accelerate time-to-market. The rising complexity of small molecule drug candidates, including antibody-drug conjugates and targeted therapies, requires CDMO expertise in advanced chemical synthesis and purification technologies. Additionally, CDMOs in Asia-Pacific and Eastern Europe provide cost advantages while progressively improving quality and regulatory compliance, attracting outsourcing contracts from Western pharmaceutical companies. This outsourcing trend drives sustained demand for intermediate manufacturing services through CDMO partnerships.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by the strong presence of major pharmaceutical companies, well-established healthcare infrastructure, and significant investment in drug development. The United States, as the world's largest pharmaceutical market, demands substantial volumes of intermediates for both innovative and generic drug production. Stringent regulatory standards in the region also encourage the use of high-quality intermediates from reliable suppliers. Additionally, the trend of reshoring pharmaceutical manufacturing to reduce reliance on foreign supply chains is gaining momentum, further supporting intermediate demand within North America. These factors collectively ensure the region maintains its dominant market position throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, fueled by rapid expansion of pharmaceutical manufacturing in China, India, and Southeast Asian nations. Low production costs, abundant raw material availability, and government initiatives promoting domestic drug production make the region an attractive destination for intermediate manufacturing. The growing outsourcing of intermediate and API production from Western markets to Asia-Pacific CDMOs further accelerates regional market growth. Additionally, rising healthcare spending, increasing chronic disease burden, and expanding generic drug consumption within the region create sustained local demand. As pharmaceutical infrastructure continues to develop, Asia-Pacific emerges as the fastest-growing market for pharmaceutical intermediates.

Key players in the market

Some of the key players in Pharmaceutical Intermediates Market include BASF SE, Lonza Group AG, Evonik Industries AG, Cambrex Corporation, Dishman Carbogen Amcis Limited, Aarti Industries Limited, Jubilant Pharmova Limited, Albemarle Corporation, Merck KGaA, Thermo Fisher Scientific Inc., Pfizer CentreOne, Boehringer Ingelheim International GmbH, CordenPharma International, Patheon N.V., Hovione Holding Ltd., WuXi AppTec Co. Ltd., Recipharm AB, Siegfried Holding AG, Laurus Labs Limited, and Dr. Reddy's Laboratories Limited.

Key Developments:

In April 2026, BASF's Aroma Ingredients business officially expanded its industrial footprint by launching three world-scale plants, including an advanced chemical building block and intermediate facility in Zhanjiang, China, following the rapid commissioning of its key regional Verbund megasite.

In March 2026, BASF's Intermediates division advanced its green manufacturing transition at the Ludwigshafen site in Germany, successfully shifting its entire commercial portfolio of acid chlorides and chloroformates to production entirely backed by 100% renewable electricity credits.

In November 2025, BASF expanded its sustainable intermediate portfolio by integrating comprehensive ISCC EU and ISCC PLUS certifications across its biomass-balanced methanol framework, supporting green chemical tracking demands within the regional biopharma supply matrix.

Product Types Covered:

  • Basic Intermediates
  • Advanced Intermediates
  • API Intermediates
  • Chiral Intermediates
  • Specialty Intermediates

Synthesis Types Covered:

  • Synthetic
  • Bio-Based
  • Fermentation-Derived

Therapeutic Areas Covered:

  • Oncology
  • Cardiovascular
  • Neurology
  • Anti-Infectives
  • Diabetes
  • Other Therapeutic Areas

Applications Covered:

  • APIs
  • Generic Drugs
  • Branded Drugs
  • Specialty Pharmaceuticals

End Users Covered:

  • Pharmaceutical Companies
  • Contract Manufacturing Organizations
  • Contract Development and Manufacturing Organizations
  • Research Institutes

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Pharmaceutical Intermediates Market, By Product Type

  • 5.1 Basic Intermediates
  • 5.2 Advanced Intermediates
  • 5.3 API Intermediates
  • 5.4 Chiral Intermediates
  • 5.5 Specialty Intermediates

6 Global Pharmaceutical Intermediates Market, By Synthesis Type

  • 6.1 Synthetic
  • 6.2 Bio-Based
  • 6.3 Fermentation-Derived

7 Global Pharmaceutical Intermediates Market, By Therapeutic Area

  • 7.1 Oncology
  • 7.2 Cardiovascular
  • 7.3 Neurology
  • 7.4 Anti-Infectives
  • 7.5 Diabetes
  • 7.6 Other Therapeutic Areas

8 Global Pharmaceutical Intermediates Market, By Application

  • 8.1 APIs
  • 8.2 Generic Drugs
  • 8.3 Branded Drugs
  • 8.4 Specialty Pharmaceuticals

9 Global Pharmaceutical Intermediates Market, By End User

  • 9.1 Pharmaceutical Companies
  • 9.2 Contract Manufacturing Organizations
  • 9.3 Contract Development and Manufacturing Organizations
  • 9.4 Research Institutes

10 Global Pharmaceutical Intermediates Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 BASF SE
  • 13.2 Lonza Group AG
  • 13.3 Evonik Industries AG
  • 13.4 Cambrex Corporation
  • 13.5 Dishman Carbogen Amcis Limited
  • 13.6 Aarti Industries Limited
  • 13.7 Jubilant Pharmova Limited
  • 13.8 Albemarle Corporation
  • 13.9 Merck KGaA
  • 13.10 Thermo Fisher Scientific Inc.
  • 13.11 Pfizer CentreOne
  • 13.12 Boehringer Ingelheim International GmbH
  • 13.13 CordenPharma International
  • 13.14 Patheon N.V.
  • 13.15 Hovione Holding Ltd.
  • 13.16 WuXi AppTec Co. Ltd.
  • 13.17 Recipharm AB
  • 13.18 Siegfried Holding AG
  • 13.19 Laurus Labs Limited
  • 13.20 Dr. Reddy's Laboratories Limited

List of Tables

  • Table 1 Global Pharmaceutical Intermediates Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Pharmaceutical Intermediates Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 3 Global Pharmaceutical Intermediates Market Outlook, By Basic Intermediates (2023-2034) ($MN)
  • Table 4 Global Pharmaceutical Intermediates Market Outlook, By Advanced Intermediates (2023-2034) ($MN)
  • Table 5 Global Pharmaceutical Intermediates Market Outlook, By API Intermediates (2023-2034) ($MN)
  • Table 6 Global Pharmaceutical Intermediates Market Outlook, By Chiral Intermediates (2023-2034) ($MN)
  • Table 7 Global Pharmaceutical Intermediates Market Outlook, By Specialty Intermediates (2023-2034) ($MN)
  • Table 8 Global Pharmaceutical Intermediates Market Outlook, By Synthesis Type (2023-2034) ($MN)
  • Table 9 Global Pharmaceutical Intermediates Market Outlook, By Synthetic (2023-2034) ($MN)
  • Table 10 Global Pharmaceutical Intermediates Market Outlook, By Bio-Based (2023-2034) ($MN)
  • Table 11 Global Pharmaceutical Intermediates Market Outlook, By Fermentation-Derived (2023-2034) ($MN)
  • Table 12 Global Pharmaceutical Intermediates Market Outlook, By Therapeutic Area (2023-2034) ($MN)
  • Table 13 Global Pharmaceutical Intermediates Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 14 Global Pharmaceutical Intermediates Market Outlook, By Cardiovascular (2023-2034) ($MN)
  • Table 15 Global Pharmaceutical Intermediates Market Outlook, By Neurology (2023-2034) ($MN)
  • Table 16 Global Pharmaceutical Intermediates Market Outlook, By Anti-Infectives (2023-2034) ($MN)
  • Table 17 Global Pharmaceutical Intermediates Market Outlook, By Diabetes (2023-2034) ($MN)
  • Table 18 Global Pharmaceutical Intermediates Market Outlook, By Other Therapeutic Areas (2023-2034) ($MN)
  • Table 19 Global Pharmaceutical Intermediates Market Outlook, By Application (2023-2034) ($MN)
  • Table 20 Global Pharmaceutical Intermediates Market Outlook, By APIs (2023-2034) ($MN)
  • Table 21 Global Pharmaceutical Intermediates Market Outlook, By Generic Drugs (2023-2034) ($MN)
  • Table 22 Global Pharmaceutical Intermediates Market Outlook, By Branded Drugs (2023-2034) ($MN)
  • Table 23 Global Pharmaceutical Intermediates Market Outlook, By Specialty Pharmaceuticals (2023-2034) ($MN)
  • Table 24 Global Pharmaceutical Intermediates Market Outlook, By End User (2023-2034) ($MN)
  • Table 25 Global Pharmaceutical Intermediates Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 26 Global Pharmaceutical Intermediates Market Outlook, By Contract Manufacturing Organizations (2023-2034) ($MN)
  • Table 27 Global Pharmaceutical Intermediates Market Outlook, By Contract Development and Manufacturing Organizations (2023-2034) ($MN)
  • Table 28 Global Pharmaceutical Intermediates Market Outlook, By Research Institutes (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.